Authors
Ikuo Nakamura, Naoto Takase, Kenjiro Iida, Mizuki Yoshida, Kazu Harada, Ami Kurimoto, Hideaki Sueoka, Masaharu Tada, Takako Kihara, Hironori Tanaka, Seiko Hirono
Published in
Case reports in oncology. Volume 19. Issue 1. Pages 1343-1355. Epub Jul 21, 2026.
Abstract
Immune checkpoint inhibitors (ICIs) are increasingly used in the treatment of biliary tract cancer; however, reports on conversion surgery following ICI-based therapy for unresectable disease are scarce.
An 83-year-old female was referred to a local hospital for further evaluation after abnormal liver function was detected during a routine health examination. Computed tomography (CT) revealed a 5 cm tumor in segment 4 of the liver, multiple liver metastases in both lobes, and metastasis to lymph node station 8. Biopsy of the tumor confirmed a diagnosis of intrahepatic cholangiocarcinoma, and the disease was determined to be unresectable due to distant metastases. After 10 courses of gemcitabine, cisplatin, and pembrolizumab (GCP) therapy, follow-up CT revealed marked shrinkage of the primary tumor in segment 4 of the liver, liver metastases, and lymph node station 8. Consequently, an extended left hepatectomy with partial resection of segments 6 and 8 was performed. The postoperative course was uneventful, and the patient was discharged on postoperative day 14. Histopathological examination revealed a pathological complete response (pCR). At 4 months postoperatively, the patient was alive without recurrence.
Reports of conversion surgery following GCP therapy are scarce, and patients achieving a pCR are extremely rare.
PMID:
42763733
Bibliographic data and abstract were imported from PubMed on 20 Sep 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 8
- Comments 0